1. Home
  2. NEUE vs BMEA Comparison

NEUE vs BMEA Comparison

Compare NEUE & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEUE
  • BMEA
  • Stock Information
  • Founded
  • NEUE 2015
  • BMEA 2017
  • Country
  • NEUE United States
  • BMEA United States
  • Employees
  • NEUE N/A
  • BMEA N/A
  • Industry
  • NEUE
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEUE
  • BMEA Health Care
  • Exchange
  • NEUE NYSE
  • BMEA Nasdaq
  • Market Cap
  • NEUE 61.2M
  • BMEA 65.8M
  • IPO Year
  • NEUE 2021
  • BMEA 2021
  • Fundamental
  • Price
  • NEUE $6.80
  • BMEA $1.54
  • Analyst Decision
  • NEUE Hold
  • BMEA Strong Buy
  • Analyst Count
  • NEUE 1
  • BMEA 11
  • Target Price
  • NEUE $7.00
  • BMEA $27.60
  • AVG Volume (30 Days)
  • NEUE 7.2K
  • BMEA 703.1K
  • Earning Date
  • NEUE 05-08-2025
  • BMEA 05-05-2025
  • Dividend Yield
  • NEUE N/A
  • BMEA N/A
  • EPS Growth
  • NEUE N/A
  • BMEA N/A
  • EPS
  • NEUE N/A
  • BMEA N/A
  • Revenue
  • NEUE $907,349,000.00
  • BMEA N/A
  • Revenue This Year
  • NEUE $33.99
  • BMEA N/A
  • Revenue Next Year
  • NEUE $5.90
  • BMEA N/A
  • P/E Ratio
  • NEUE N/A
  • BMEA N/A
  • Revenue Growth
  • NEUE N/A
  • BMEA N/A
  • 52 Week Low
  • NEUE $3.79
  • BMEA $1.29
  • 52 Week High
  • NEUE $7.66
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • NEUE 51.38
  • BMEA 40.48
  • Support Level
  • NEUE $6.66
  • BMEA $1.29
  • Resistance Level
  • NEUE $6.87
  • BMEA $1.52
  • Average True Range (ATR)
  • NEUE 0.10
  • BMEA 0.13
  • MACD
  • NEUE -0.01
  • BMEA 0.01
  • Stochastic Oscillator
  • NEUE 48.28
  • BMEA 31.00

About NEUE NEUEHEALTH INC

NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: